Akademik Veri Yönetim Sistemi
European Committee for Treatment and Research in Multiple Sclerosis, Milan, İtalya, 11 - 13 Ekim 2023, cilt.29, sa.3, ss.802-803
Introduction: Schisandrin B is a bioactive compound naturally found in Schisandra rubriflora. We have previously reported that Schisandrin B, when given prophylactically, improved experimental autoimmune encephalomyelitis (EAE).
Objectives/Aims: In the current study, we aimed to study its impact on EAE when given after disease induction, and its in vitro effects on murine lymphocytes and helper T cell differentiation.
Methods: CD57BL/6-MOG35-55 and SJL/J-PLP139-151 mice were used for EAE induction. Mouse splenocytes and lymphocytes were used for in vitro experiments.
Results: Schisandrin B treatment after 8 days after MOG35-55 immunization marginally affected EAE disease scores and area under curve in C57BL/6 mice. Additionally, Schisandrin B slightly reduced GM-CSF and IL-22 production by CD4+ T cells in the draining lymph nodes in SJL/j mice following PLP139-151 immunization. Although no effect was seen in inguinal lymph nodes, cervical lymph nodes showed reduced IL-2 production by CD4+ or CD8+ T cells, a week after the immunizations in SJL/J mice. Importantly, CD25 expression was slightly higher by Treg cells in the cervical lymph nodes of SJL/J mice a week after the immunizations. On the 9th day of immunizations, infiltrating leukocytes in the central nervous system showed reduced CD3+ and CD8+ T cell frequency, and reduced activation as marked by lower CD25 expression. In vitro experiments showed that Schisandrin B dampened IL-6 and MIP-1α by T cells and splenocytes, respectively, and that it blocked Th1 and Th17 T cell polarization significantly at 10 μM doses.
Conclusion: Collectively these results suggest an immunomodulatory role for Schisandrin B and its potential in inflammatory conditions like MS.
Disclosure of interest: nothing to disclose